

Members Obtain Free CE Credits from JCP Articles!



Drug-Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives

July 2022 – *The Journal of Clinical Pharmacology* (JCP)

Why is this article important to you?

Despite the advancement of antiretroviral therapy (ART) for the treatment of human immunodeficiency virus (HIV), drug–drug interactions (DDIs) remain a relevant clinical issue for people living with HIV receiving ART. Antiretroviral (ARV) drugs can be victims and perpetrators of DDIs and a detailed investigation during drug discovery and development is required to determine whether dose adjustments are necessary or coadministrations are contraindicated. Maintaining therapeutic ARV plasma concentrations is essential for successful ART and changes resulting from potential DDIs could lead to toxicity, treatment failure or the emergence of ARV-resistant HIV. The challenges surrounding DDI management are complex in special populations of people living with HIV and often lack evidence-based guidance as a result of their underrepresentation in clinical investigations. Specifically, the prevalence of hepatic and renal impairment in people living with HIV are between five and 10 times greater than in people who are HIV-negative, with each condition constituting approximately 15% of non-AIDS-related mortality. Therapeutic strategies tend to revolve around the treatment of risk factors that lead to hepatic and renal impairment, such as hepatitis C, hepatitis B, hypertension, hyperlipidemia and diabetes. These strategies result in a diverse range of potential DDIs with ART. Learners that complete this activity will be able to identify current pharmacokinetic DDIs and their mechanisms between ARVs and co-medications used for the prevention and treatment of hepatic and renal impairment in people living with HIV.

ACPE Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

UAN: 0665-0000-22-031-H01-P– ACPE 1 Contact Hours

Activity Type: Knowledge-based **Format:** Home-study **Target Audience:** ‘P’



ACCME Accreditation Statement

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ACCME Designation Statement

The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.



Target Audience

Interprofessional team of Physicians, Pharmacists and PhDs.

Learning Objectives

After completing this activity, the learner will be able to:

1. Identify existing knowledge gaps surrounding DDIs related to special populations of hepatic and renal impairment in people living with HIV;
2. Identify challenges surrounding DDI management in special populations of people living with HIV.

Requirements to Receive Credit

To receive continuing education credit, the learner must register for the educational activity, study the provided journal article and complete the online learning Post-event Self-assessment, as well as the online course Evaluation and CME/CPE Certificate. Credits and CME/CPE Certificates must be claimed within thirty (30) days of completing the article, Post-event Self-Assessment and Evaluation. Contact CE@ACCP1.org with any questions.

Disclosures:

Article Selection: Joseph S. Bertino Jr, PharmD, planner for this educational activity, has no relevant relationship(s) with ineligible companies to disclose.

Planners: Sonia Pahwa, PhD, planner for this educational activity, has no relevant relationship(s) with ineligible companies to disclose.

CE Reviewer: Alexander Sperry, PharmD, reviewer for this educational activity, has no relevant relationship(s) with ineligible companies to disclose.

Schedule & Fees

JCP monthly Journal CE articles are generally released on the 1st or 2nd Tuesday of each month. They are priced in packages of January to December for each year. Packages are available at no cost to ACCP Members and \$75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

Acknowledgement of Financial Support

No financial support was received for this educational activity.

Home Study Initial Release and Expiration Dates

Date of Issuance: 06/01/2022

Expiration Date: 06/01/2025

Helpful Tips

Download the article and access the Self-assessment Post-test, Evaluation and Certificate [here](#).

Learn how to print your CME/CPE Certificate [here](#).
